Regeneron Pharmaceuticals Inc (REGN) Position Boosted by Norinchukin Bank The

Norinchukin Bank The lifted its holdings in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 7.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,160 shares of the biopharmaceutical company’s stock after purchasing an additional 441 shares during the period. Norinchukin Bank The’s holdings in Regeneron Pharmaceuticals were worth $2,316,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also made changes to their positions in REGN. Steward Partners Investment Advisory LLC increased its stake in shares of Regeneron Pharmaceuticals by 495.2% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 369 shares of the biopharmaceutical company’s stock valued at $138,000 after purchasing an additional 307 shares in the last quarter. Advisory Services Network LLC increased its stake in shares of Regeneron Pharmaceuticals by 147.0% in the 4th quarter. Advisory Services Network LLC now owns 447 shares of the biopharmaceutical company’s stock valued at $168,000 after purchasing an additional 266 shares in the last quarter. Vident Investment Advisory LLC purchased a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at about $200,000. Virtu KCG Holdings LLC purchased a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at about $206,000. Finally, AE Wealth Management LLC purchased a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at about $206,000. Hedge funds and other institutional investors own 64.67% of the company’s stock.

REGN has been the subject of several recent analyst reports. BTIG Research restated a “buy” rating and issued a $520.00 price target on shares of Regeneron Pharmaceuticals in a research note on Wednesday, November 22nd. Piper Jaffray Companies reiterated a “buy” rating and issued a $540.00 price objective on shares of Regeneron Pharmaceuticals in a report on Monday, November 13th. Citigroup reiterated a “buy” rating and issued a $480.00 price objective on shares of Regeneron Pharmaceuticals in a report on Thursday, November 9th. Argus lowered their price objective on Regeneron Pharmaceuticals from $540.00 to $470.00 and set a “buy” rating on the stock in a report on Thursday, December 28th. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $522.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, February 7th. Three research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. Regeneron Pharmaceuticals has an average rating of “Hold” and an average target price of $450.65.

Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) opened at $317.51 on Thursday. The company has a market cap of $34,790.12, a P/E ratio of 23.38, a PEG ratio of 1.01 and a beta of 1.47. The company has a current ratio of 3.82, a quick ratio of 3.18 and a debt-to-equity ratio of 0.11. Regeneron Pharmaceuticals Inc has a 12-month low of $313.53 and a 12-month high of $543.55.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported $5.23 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $4.18 by $1.05. The firm had revenue of $1.58 billion for the quarter, compared to analyst estimates of $1.50 billion. Regeneron Pharmaceuticals had a net margin of 20.41% and a return on equity of 28.48%. The business’s revenue for the quarter was up 28.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $3.04 EPS. analysts forecast that Regeneron Pharmaceuticals Inc will post 19.2 earnings per share for the current year.

In other Regeneron Pharmaceuticals news, Director Joseph L. Goldstein sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $325.60, for a total value of $325,600.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 10.80% of the stock is owned by insiders.

COPYRIGHT VIOLATION WARNING: “Regeneron Pharmaceuticals Inc (REGN) Position Boosted by Norinchukin Bank The” was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this piece of content can be read at https://ledgergazette.com/2018/02/22/regeneron-pharmaceuticals-inc-regn-position-boosted-by-norinchukin-bank-the.html.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply